Clinical Trial News and Research

RSS

Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.

8 May 2015

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.

8 May 2015

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

A novel investigational West Nile virus vaccine discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University is being evaluated in an NIH-sponsored Phase 1, first-in-human, clinical trial at Duke University. Although several early-stage West Nile virus vaccine clinical trials have been completed to date, no human vaccine has been approved for commercial use.

7 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

DePuy Synthes CMF today announced the launch of SYNTHECEL Dura Repair, the first commercially available biosynthesized dural replacement derived from cellulose for use in neurosurgery. DePuy Synthes CMF is a part of the DePuy Synthes Companies of Johnson & Johnson.

7 May 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

6 May 2015

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper Pharmaceuticals, Inc., today announced financial results for the three-month period ended March 31, 2015.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US.

5 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.

4 May 2015

Keynote 24 study explores investigational approach to treating lung cancer

Lung cancer impacts the lives of millions of people worldwide. In nearly 40 percent of people diagnosed with lung cancer, it has metastasized, or spread to other areas of the body, making it difficult to treat. Immunotherapy is a type of therapy that uses the body's own immune system to help fight cancer. Immunotherapy may help the body's immune system target cancer cells.

30 Apr 2015

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific announces the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems.

30 Apr 2015

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar Pharmaceuticals, Inc., today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.

30 Apr 2015

HeartWare International's revenue increases 5% to $70.0 million in first quarter 2015

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $70.0 million for the first quarter ended March 31, 2015, a five percent increase compared to $66.5 million in revenue for the same period of 2014.

30 Apr 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC).

30 Apr 2015

Lung volume reduction surgery could improve lung function in emphysema patients

Emphysema is a chronic, progressive, obstructive lung disease in which the small sacs of the lung (alveoli) are destroyed, leading to air pockets and severe breathing difficulties. In 2011, 4.7 million Americans reported being diagnosed with emphysema, and in 2013 more than 8200 patients died from emphysema.

30 Apr 2015

Clinical Trial News and Research

Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

Researchers identify multiple types of resistance to new targeted lung cancer drug

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Keynote 24 study explores investigational approach to treating lung cancer

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

HeartWare International's revenue increases 5% to $70.0 million in first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

Lung volume reduction surgery could improve lung function in emphysema patients

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer